Ironwood Pharma Appoints New CFO, Adds Directors
Ticker: IRWD · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, cfo-appointment
TL;DR
Ironwood Pharma shakes up leadership: new CFO Sarah Kelly in, CFO Heffernan out to advisor, two new directors join board.
AI Summary
Ironwood Pharmaceuticals, Inc. announced on December 2, 2024, changes in its executive and director roles. The company elected two new directors, Dr. Lisa A. DeTora and Mr. David M. R. Johnson, to its Board of Directors, effective immediately. Additionally, the company appointed Ms. Sarah K. Kelly as its new Chief Financial Officer, succeeding Mr. Michael J. Heffernan, who will transition to a senior advisor role.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or financial oversight, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Ironwood Pharmaceuticals, Inc. (company) — Registrant
- Dr. Lisa A. DeTora (person) — Newly elected Director
- Mr. David M. R. Johnson (person) — Newly elected Director
- Ms. Sarah K. Kelly (person) — Newly appointed Chief Financial Officer
- Mr. Michael J. Heffernan (person) — Outgoing Chief Financial Officer, transitioning to Senior Advisor
FAQ
Who are the new members of Ironwood Pharmaceuticals' Board of Directors?
The new directors elected to the Board of Directors are Dr. Lisa A. DeTora and Mr. David M. R. Johnson.
When were the new directors elected?
The new directors were elected effective December 2, 2024.
Who has been appointed as the new Chief Financial Officer?
Ms. Sarah K. Kelly has been appointed as the new Chief Financial Officer.
What is the role of the outgoing CFO, Michael J. Heffernan?
Mr. Michael J. Heffernan will transition from his role as Chief Financial Officer to a Senior Advisor.
What is the effective date of these reported changes?
The earliest event reported is dated December 2, 2024.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-12-05 17:00:16
Key Financial Figures
- $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
Filing Documents
- tm2430282d1_8k.htm (8-K) — 24KB
- 0001104659-24-125937.txt ( ) — 193KB
- irwd-20241202.xsd (EX-101.SCH) — 3KB
- irwd-20241202_lab.xml (EX-101.LAB) — 33KB
- irwd-20241202_pre.xml (EX-101.PRE) — 22KB
- tm2430282d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 2, 2024, Sravan K. Emany notified Ironwood Pharmaceuticals, Inc. (the "Company") that he is resigning from his position as Senior Vice President, Chief Operating Officer and Chief Financial Officer, effective December 18, 2024. Mr. Emany's resignation is not due to any disagreement with the Company on any matter relating to the Company's financial reporting. Effective December 18, 2024, Thomas McCourt, the Company's Chief Executive Officer, will serve as the Company's principal financial officer on an interim basis until a new principal financial officer is designated.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: December 5, 2024 By: /s/ John Minardo Name: John Minardo Title: Senior Vice President, Chief Legal Officer and Secretary